JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

Search

Globus Medical Inc (Class A)

Slēgts

SektorsVeselības aprūpe

89.62 -1.11

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

88.99

Max

90.63

Galvenie mērījumi

By Trading Economics

Ienākumi

-84M

119M

Pārdošana

24M

769M

P/E

Sektora vidējais

30.091

90.422

EPS

1.18

Peļņas marža

15.469

Darbinieki

5,300

EBITDA

22M

215M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+17.45% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 24. febr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

4.3B

13B

Iepriekšējā atvēršanas cena

90.73

Iepriekšējā slēgšanas cena

89.62

Ziņu noskaņojums

By Acuity

71%

29%

324 / 352 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

Globus Medical Inc (Class A) Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 2. febr. 23:52 UTC

Iegādes, apvienošanās, pārņemšana

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2026. g. 2. febr. 23:52 UTC

Iegādes, apvienošanās, pārņemšana

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2026. g. 2. febr. 23:48 UTC

Tirgus saruna

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2026. g. 2. febr. 23:38 UTC

Tirgus saruna

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2026. g. 2. febr. 23:28 UTC

Tirgus saruna

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2026. g. 2. febr. 23:23 UTC

Peļņas

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2026. g. 2. febr. 22:57 UTC

Peļņas

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026. g. 2. febr. 22:22 UTC

Iegādes, apvienošanās, pārņemšana

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2026. g. 2. febr. 22:08 UTC

Tirgus saruna

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2026. g. 2. febr. 21:51 UTC

Peļņas

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026. g. 2. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 2. febr. 21:49 UTC

Peļņas

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2026. g. 2. febr. 21:39 UTC

Peļņas

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026. g. 2. febr. 21:36 UTC

Peļņas

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2026. g. 2. febr. 21:34 UTC

Peļņas

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026. g. 2. febr. 21:28 UTC

Iegādes, apvienošanās, pārņemšana

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2026. g. 2. febr. 21:23 UTC

Peļņas

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2026. g. 2. febr. 21:19 UTC

Peļņas

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2026. g. 2. febr. 21:17 UTC

Peļņas

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2026. g. 2. febr. 21:17 UTC

Peļņas

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026. g. 2. febr. 21:10 UTC

Peļņas

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026. g. 2. febr. 21:08 UTC

Peļņas

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2026. g. 2. febr. 21:07 UTC

Peļņas

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2026. g. 2. febr. 21:05 UTC

Peļņas

Palantir Technologies 4Q Net $608.7M >PLTR

2026. g. 2. febr. 21:05 UTC

Peļņas

Palantir Technologies 4Q Rev $1.41B >PLTR

2026. g. 2. febr. 21:05 UTC

Peļņas

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2026. g. 2. febr. 21:05 UTC

Peļņas

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2026. g. 2. febr. 21:05 UTC

Peļņas

Palantir Technologies 4Q Adj EPS 25c >PLTR

2026. g. 2. febr. 21:05 UTC

Peļņas

Palantir Technologies 4Q EPS 24c >PLTR

2026. g. 2. febr. 20:40 UTC

Tirgus saruna

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Salīdzinājums

Cenas izmaiņa

Globus Medical Inc (Class A) Prognoze

Cenas mērķis

By TipRanks

17.45% augšup

Prognoze 12 mēnešiem

Vidējais 106.5 USD  17.45%

Augstākais 118 USD

Zemākais 87 USD

Pamatojoties uz 14 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Globus Medical Inc (Class A) — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

14 ratings

11

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

72.18 / 73.07Atbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Weak Bearish Evidence

Noskaņojums

By Acuity

324 / 352 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Globus Medical Inc (Class A)

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
help-icon Live chat